According to a market report by Lucintel, the future of the global structural heart device market looks promising with opportunities in the aorta and mitral markets. The global structural heart device market is expected to reach an estimated $26,993 million by 2035 with a CAGR of 8.9% from 2025 to 2035. The major drivers for this market are the growing adoption of advanced imaging and diagnostic tools, the rising demand for technological advancements in structural heart devices, and the increasing adoption for prevalence of lifestyle-related heart conditions.
A more
than 150-page report to understand trends, opportunity and forecast in global structural
heart device market to 2035 by procedure (repair and replacement), position
(aorta, mitral, and others), and region (North America, Europe, Asia Pacific,
and the Rest of the World).
Lucintel
forecasts that, within the procedure category, repair is expected to witness
higher growth over the forecast period.
Within the
position category, aorta is expected to witness the highest growth.
Download
sample by clicking on structural
heart device market.
In terms
of region, APAC is expected to witness the highest growth over the forecast period.
St. Jude
Medical, Inc., Boston Scientific Corporation, Abbott Laboratories, Edwards
Lifesciences Corporation, Medtronic Public Limited Company, LivaNova PLC, C. R.
Bard, Inc., CryoLife Inc., JenaValve Technology Inc., Lepu Medical Technology
(Beijing) Co., Ltd. are the major suppliers in the structural heart device market.
This unique research
report will enable you to make confident business decisions in this globally
competitive marketplace. For a detailed table of contents, contact Lucintel at
+1-972-636-5056 or write us at helpdesk@lucintel.com. To get access of more than 1000 reports at fraction of cost
visit Lucintel's Analytics
Dashboard.
About Lucintel
At Lucintel, we offer solutions for
you growth through game changer ideas and robust market &
unmet needs analysis. We are based in
Dallas, TX and have been a trusted advisor for 1,000+ clients for over 20
years. We are quoted in several publications like the Wall Street Journal,
ZACKS, and the Financial Times.
Contact:
Roy Almaguer
Lucintel
Dallas, Texas, USA
Email: roy.almaguer@lucintel.com
Tel. +1-972-636-5056
Explore Our Latest Publications
Apomorphine Hydrochloride Market
No comments:
Post a Comment